KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Other Non-Current Liabilities (2019 - 2025)

GoodRx Holdings (GDRX) has disclosed Other Non-Current Liabilities for 7 consecutive years, with $8.7 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities rose 29.4% to $8.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.7 million through Dec 2025, up 29.4% year-over-year, with the annual reading at $8.7 million for FY2025, 29.4% up from the prior year.
  • Other Non-Current Liabilities hit $8.7 million in Q4 2025 for GoodRx Holdings, up from $7.6 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $9.6 million in Q2 2023 to a low of $4.7 million in Q1 2022.
  • Historically, Other Non-Current Liabilities has averaged $7.4 million across 5 years, with a median of $7.6 million in 2022.
  • Biggest five-year swings in Other Non-Current Liabilities: fell 25.09% in 2022 and later soared 70.04% in 2023.
  • Year by year, Other Non-Current Liabilities stood at $5.4 million in 2021, then soared by 40.41% to $7.6 million in 2022, then increased by 8.2% to $8.2 million in 2023, then decreased by 17.39% to $6.8 million in 2024, then increased by 29.4% to $8.7 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for GDRX at $8.7 million in Q4 2025, $7.6 million in Q3 2025, and $7.0 million in Q2 2025.